Trial intelligence / Profile preview

CNI-Sparing in Steroid-free Kidney Transplantation

NCT01062555Phase 2

Key facts

Status
Completed
Start
Oct 2006
Primary completion
Apr 2014
Countries
1
Sponsor
University of Minnesota
Modality
Small Molecules
Conditions
kidney transplantation
01

Overview

Phase 2, randomised, open-label trial of sirolimus in kidney transplantation, sponsored by University of Minnesota. Started Oct 2006; status: completed.

02

Design

Study design
RandomizedOpen-label
03

Registry description

Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant function in those who have had their transplants for many years. The introduction of new immunosuppression medications however, has provided the opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the kidney.

Beyond the preview

Go deeper on NCT01062555.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01062555.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call